stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Gross margin
Sarepta Therapeutics, Inc.'s gross margin over the twelve months to 30 September 2026 was 0.00%, down 61.8 percentage points from fiscal 2025 (61.8%). Over the past ten years it has ranged from 61.8% (fiscal 2025) to 100.0% (fiscal 2015) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 68.5% and below the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 61.8% | (21.41) |
| FY2024 | 83.2% | (4.69) |
| FY2023 | 87.9% | 2.91 |
| FY2022 | 85.0% | (1.17) |
| FY2021 | 86.2% | (2.09) |
| FY2020 | 88.3% | 3.12 |
| FY2019 | 85.1% | (3.50) |
| FY2018 | 88.6% | (6.60) |
| FY2017 | 95.2% | (2.90) |
| FY2016 | 98.1% | (1.86) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | (62.77) |
| Jun 2026 | 62.8% | (22.35) |
| Mar 2026 | 85.1% | 75.14 |
| Dec 2025 | 9.98% | (52.27) |
| 35 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| VIR Vir Biotechnology, Inc. compare | 100.0% |
| HRMY Harmony Biosciences Holdings, Inc. compare | 74.0% |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 39.2% |
| SRPT Sarepta Therapeutics, Inc. | 0.00% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRVI Trevi Therapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | −269.7% |
| MAZE Maze Therapeutics, Inc. compare | — |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| Biotechnology industry median | 68.5% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue